RT @DrKanikaMonga: Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical St…
Tweet Content
Efficacy and Safety of Upadacitinib in a
Randomized, Double-Blind, Placebo-Controlled,
Multicenter Phase 2/3 Clinical Study of Patients With Active AS
• Onset of response to upadacitinib 15 mg QD tx was rapid
• AEs similar between upadacitinib and placebo
#ACR19 @RheumNow
Show on Archive Page
On
Display in Search Results
On